With the recent rise of news surrounding COVID-19 treatments and vaccines, companies working in the space such as Gilead Sciences has seen their stock's share price rise nearly 30% since January, 21, 2020. Adding over $20 Billion to their market cap.
This leaves good reason to speculate that Inspyr Therapeutics can prove to be a pivotal player in the race to provide treatments to 100s of millions of people that may require treatment just in the United States alone over the coming months (or maybe years). Their technology and long list of patents may leverage their value to secure partner deal with a top biotech company like Gilead, Roche, and others currently working on treatments and vaccines, or increasing the probability for an outright acquisition of Inspyr.
Also, to note, the intellectual property (IP) supporting Inspyr Therapeutics (formerly known as GenSpera) technology was developed over 15 years at Johns Hopkins University and the University of Copenhagen with over $15 million in scientific grants from the National Cancer Institute, the U.S. Department of Defense, and the U.S. National Institutes of Health, among others. Their IP portfolio contains several issued patents and along with several pending patent applications. As reported by Crunchbase, Inspyr Therapeutics has raised $22.8 million.
According to Inspyr's latest share price and filings, they have 11,383,983 outstanding shares and a market cap of about $30,000. For a company that has such promising therapies for cancer and potentially the treatment of COVID-19 symptoms, one would think this company is grossly undervalued.
You can learn more about Inspyr Therapeutics here:
